Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.

Beliakova-Bethell N, Mukim A, White CH, Deshmukh S, Abewe H, Richman DD, Spina CA.

J Biol Chem. 2019 Apr 5;294(14):5576-5589. doi: 10.1074/jbc.RA118.005185. Epub 2019 Feb 11.

PMID:
30745362
2.

Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment.

White CH, Beliakova-Bethell N, Lada SM, Breen MS, Hurst TP, Spina CA, Richman DD, Frater J, Magiorkinis G, Woelk CH.

Front Immunol. 2018 Apr 12;9:603. doi: 10.3389/fimmu.2018.00603. eCollection 2018.

3.

Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART.

Beliakova-Bethell N, Hezareh M, Wong JK, Strain MC, Lewinski MK, Richman DD, Spina CA.

Virology. 2017 Aug;508:127-133. doi: 10.1016/j.virol.2017.05.008.

4.

Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model.

White CH, Moesker B, Beliakova-Bethell N, Martins LJ, Spina CA, Margolis DM, Richman DD, Planelles V, Bosque A, Woelk CH.

PLoS Pathog. 2016 Nov 29;12(11):e1006026. doi: 10.1371/journal.ppat.1006026. eCollection 2016 Nov.

5.

Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART.

Dan JM, Massanella M, Smith DM, Spina CA, Schrier R, Daar ES, Dube MP, Morris SR, Gianella S.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):133-7. doi: 10.1097/QAI.0000000000000936.

6.

Pharmacologic Inhibition of Nedd8 Activation Enzyme Exposes CD4-Induced Epitopes within Env on Cells Expressing HIV-1.

Tokarev A, Stoneham C, Lewinski MK, Mukim A, Deshmukh S, Vollbrecht T, Spina CA, Guatelli J.

J Virol. 2015 Dec 16;90(5):2486-502. doi: 10.1128/JVI.02736-15.

7.

Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency.

White CH, Johnston HE, Moesker B, Manousopoulou A, Margolis DM, Richman DD, Spina CA, Garbis SD, Woelk CH, Beliakova-Bethell N.

Antiviral Res. 2015 Nov;123:78-85. doi: 10.1016/j.antiviral.2015.09.002. Epub 2015 Sep 4.

8.

Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.

Reardon B, Beliakova-Bethell N, Spina CA, Singhania A, Margolis DM, Richman DR, Woelk CH.

AIDS. 2015 Nov;29(17):2235-44. doi: 10.1097/QAD.0000000000000839.

9.

Sulfonation pathway inhibitors block reactivation of latent HIV-1.

Murry JP, Godoy J, Mukim A, Swann J, Bruce JW, Ahlquist P, Bosque A, Planelles V, Spina CA, Young JA.

Virology. 2014 Dec;471-473:1-12. doi: 10.1016/j.virol.2014.08.016. Epub 2014 Oct 11.

10.

Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment.

Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube MP, Haubrich RH, Morris SR, Smith DM; California Collaborative Treatment Group 592 Team.

J Virol. 2014 Jul;88(14):7818-27. doi: 10.1128/JVI.00831-14. Epub 2014 Apr 30.

11.

Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.

Beliakova-Bethell N, Jain S, Woelk CH, Witt MD, Sun X, Lada SM, Spina CA, Goicoechea M, Rought SE, Haubrich R, Dubé MP.

Antiviral Res. 2014 Jul;107:42-9. doi: 10.1016/j.antiviral.2014.04.005. Epub 2014 Apr 24.

12.

Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T.

PLoS Pathog. 2014 Apr 10;10(4):e1004071. doi: 10.1371/journal.ppat.1004071. eCollection 2014 Apr.

13.

An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.

Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V.

PLoS Pathog. 2013;9(12):e1003834. doi: 10.1371/journal.ppat.1003834. Epub 2013 Dec 26.

14.

Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection.

Pérez-Santiago J, Gianella S, Massanella M, Spina CA, Karris MY, Var SR, Patel D, Jordan PS, Young JA, Little SJ, Richman DD, Smith DM.

AIDS. 2013 Jul 31;27(12):1921-31.

15.

The effect of cell subset isolation method on gene expression in leukocytes.

Beliakova-Bethell N, Massanella M, White C, Lada S, Du P, Vaida F, Blanco J, Spina CA, Woelk CH.

Cytometry A. 2014 Jan;85(1):94-104. doi: 10.1002/cyto.a.22352. Epub 2013 Sep 20.

16.

Highly precise measurement of HIV DNA by droplet digital PCR.

Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, Spina CA, Woelk CH, Richman DD.

PLoS One. 2013;8(4):e55943. doi: 10.1371/journal.pone.0055943. Epub 2013 Apr 3.

17.

Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells.

Beliakova-Bethell N, Zhang JX, Singhania A, Lee V, Terry VH, Richman DD, Spina CA, Woelk CH.

AIDS. 2013 Jan 2;27(1):29-37. doi: 10.1097/QAD.0b013e32835b3e26.

18.

Microwell devices with finger-like channels for long-term imaging of HIV-1 expression kinetics in primary human lymphocytes.

Razooky BS, Gutierrez E, Terry VH, Spina CA, Groisman A, Weinberger LS.

Lab Chip. 2012 Nov 7;12(21):4305-12. doi: 10.1039/c2lc40170c.

19.

Cell-intrinsic mechanism involving Siglec-5 associated with divergent outcomes of HIV-1 infection in human and chimpanzee CD4 T cells.

Soto PC, Karris MY, Spina CA, Richman DD, Varki A.

J Mol Med (Berl). 2013 Feb;91(2):261-70. doi: 10.1007/s00109-012-0951-7. Epub 2012 Sep 4.

20.

Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract.

Gianella S, Morris SR, Anderson C, Spina CA, Vargas MV, Young JA, Richman DD, Little SJ, Smith DM.

AIDS. 2013 Jan 2;27(1):39-47. doi: 10.1097/QAD.0b013e3283573305.

21.

Associations between virologic and immunologic dynamics in blood and in the male genital tract.

Gianella S, Strain MC, Rought SE, Vargas MV, Little SJ, Richman DD, Spina CA, Smith DM.

J Virol. 2012 Feb;86(3):1307-15. doi: 10.1128/JVI.06077-11. Epub 2011 Nov 23.

22.

CD44 microbeads accelerate HIV-1 infection in T cells.

Terry VH, Johnston IC, Spina CA.

Virology. 2009 Jun 5;388(2):294-304. doi: 10.1016/j.virol.2009.03.022. Epub 2009 Apr 23. Erratum in: Virology. 2011 Oct 10;419(1):54-5.

23.

Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro.

Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, Ignacio CC, Campos-Soto P, Little SJ, Shafer R, Robbins GK, D'Aquila RT, Kawano Y, Young K, Dao P, Spina CA, Richman DD, Wong JK.

J Infect Dis. 2008 Feb 1;197(3):411-9. doi: 10.1086/525283.

24.

Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro.

Stone GW, Barzee S, Snarsky V, Spina CA, Lifson JD, Pillai VK, Amara RR, Villinger F, Kornbluth RS.

Clin Vaccine Immunol. 2006 Nov;13(11):1223-30. Epub 2006 Sep 20.

25.

Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF, Kornbluth RS.

J Virol. 2006 Feb;80(4):1762-72.

26.

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM.

Lancet. 2005 Aug 13-19;366(9485):549-55.

27.

Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, Daly OA, Nguyen J, Ignacio CC, Spina CA, Richman DD, Wong JK.

J Infect Dis. 2005 May 1;191(9):1410-8. Epub 2005 Mar 29.

28.

Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection.

Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, Dong T, Chesney G, Waters A, Easterbrook P, Dunbar PR, Shepherd D, Cerundolo V, Emery V, Griffiths P, Conlon C, McMichael AJ, Richman DD, Rowland-Jones SL, Appay V.

PLoS Biol. 2004 Feb;2(2):E20. Epub 2004 Feb 17. Review.

29.

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Strain MC, Günthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, Macaranas TR, Lam RY, Daly OA, Fischer M, Opravil M, Levine H, Bacheler L, Spina CA, Richman DD, Wong JK.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4819-24. Epub 2003 Apr 8.

30.

Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL.

Nat Med. 2002 Apr;8(4):379-85.

PMID:
11927944
31.

Dynamics of T cell responses in HIV infection.

Appay V, Papagno L, Spina CA, Hansasuta P, King A, Jones L, Ogg GS, Little S, McMichael AJ, Richman DD, Rowland-Jones SL.

J Immunol. 2002 Apr 1;168(7):3660-6. Erratum in: J Immunol 2002 Jul 1;169(1):607.

32.

Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression.

Appay V, Hansasuta P, Sutton J, Schrier RD, Wong JK, Furtado M, Havlir DV, Wolinsky SM, McMichael AJ, Richman DD, Rowland-Jones SL, Spina CA.

AIDS. 2002 Jan 25;16(2):161-70.

PMID:
11807299
33.

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function.

Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV, Richman DD, Waters A, Easterbrook P, McMichael AJ, Rowland-Jones SL.

J Exp Med. 2000 Jul 3;192(1):63-75.

34.

Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.

Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD.

J Infect Dis. 2000 Feb;181(2):522-31.

PMID:
10669335
35.

Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.

Günthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, Perelson AS, Spina CA, Havlir DV, Hezareh M, Looney DJ, Richman DD, Wong JK.

J Virol. 1999 Nov;73(11):9404-12.

36.

Viral dynamics of acute HIV-1 infection.

Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV.

J Exp Med. 1999 Sep 20;190(6):841-50.

37.

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD.

Science. 1997 Nov 14;278(5341):1291-5.

38.
39.

Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein.

Pandori MW, Fitch NJ, Craig HM, Richman DD, Spina CA, Guatelli JC.

J Virol. 1996 Jul;70(7):4283-90.

40.
42.

Cell surface CD4 downregulation and resistance to superinfection induced by a defective provirus of HIV-1.

Little SJ, Riggs NL, Chowers MY, Fitch NJ, Richman DD, Spina CA, Guatelli JC.

Virology. 1994 Dec;205(2):578-82.

PMID:
7975260
43.

Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.

Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, Guatelli JC.

J Virol. 1994 May;68(5):2906-14.

44.
46.

Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies.

Zarling JM, Moran PA, Haffar O, Sias J, Richman DD, Spina CA, Myers DE, Kuebelbeck V, Ledbetter JA, Uckun FM.

Nature. 1990 Sep 6;347(6288):92-5.

PMID:
1975641
47.

Alterations in cytotoxic and phenotypic subsets of natural killer cells in acquired immune deficiency syndrome (AIDS).

Plaeger-Marshall S, Spina CA, Giorgi JV, Mitsuyasu R, Wolfe P, Gottlieb M, Beall G.

J Clin Immunol. 1987 Jan;7(1):16-23.

PMID:
3104390
48.

The use of three baseline values in intervention studies: application to evaluation of immune modulation therapies.

Korn EL, Dorey F, Spina CA, Fahey JL.

Immunobiology. 1984 Dec;167(5):431-6.

PMID:
6526422
49.

Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer.

Berek JS, Bast RC Jr, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, Knapp RC, Zighelboim J.

Obstet Gynecol. 1984 Nov;64(5):708-14.

PMID:
6493663
50.

Therapeutic trials in multiple sclerosis: azathioprine.

Ellison GW, Myers LW, Mickey MR, Frane MV, Tourtellotte WW, Spina CA, Fahey JL.

Ann N Y Acad Sci. 1984;436:361-5. No abstract available.

PMID:
6398018

Supplemental Content

Loading ...
Support Center